AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01298258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150mg
Study NCT03147963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given until progression or patient intolerance
Study NCT03147963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be given until progression or patient intolerance
Study NCT02551146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A Locator with retention elements
Description: Insertion of GC Pilier locator abutments with retention elements
Study NCT02551146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B Locator without retention elements
Description: Insertion of GC Pilier locator abutments without retention elements
Study NCT03056924 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pneumococcal Pneumonia vaccine
Description: Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
Study NCT03056924 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza vaccine
Description: Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
Study NCT03056924 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
Study NCT01399996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt smoothie without probiotic
Description: A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
Study NCT01399996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with probiotic added post fermentation
Description: A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
Study NCT01399996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with probiotic added pre-fermentation
Description: A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
Study NCT01399996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A capsule containing the probiotic
Description: A capsule taken daily will provide between 10x\^y9 and 10x\^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
Study NCT04144816 — intervention group
Intervention type: OTHER
Intervention: Not applicable (no intervention)
Description: Not applicable (no intervention)
Study NCT01452256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: 4-6 Vol %
Study NCT01452256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: TIVA to achieve BIS value of 40-60
Study NCT02421042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 5- or 10-mg single oral dose of E7080, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].
Study NCT03163966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086 capsules
Study NCT03163966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral Methotrexate tablets
Study NCT03163966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral CR6086 Placebo capsules
Study NCT03315260 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glasdegib
Description: Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Study NCT00430508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
Study NCT00430508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
Study NCT00430508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil/hydrochlorothiazide tablets
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
Study NCT00430508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil/hydrochlorothiazide tablets
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
Study NCT03390062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
Study NCT02260843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic Fitness
Description: Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
Study NCT02260843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi Intervention
Description: Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
Study NCT01707693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity Intervention
Description: Physical Activity Information given plus Behavioral counseling using motivational interviewing \& follow-up
Study NCT01707693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information / Attention Comparison
Description: Physical Activity information given \& follow-up, no behavioral counseling
Study NCT03055975 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of residual vital bacteria in the root canal space
Description: Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
Study NCT01777581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Study NCT01777581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03115151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
Study NCT03115151 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
Study NCT03115151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin + cytarabine
Description: '7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: daunorubicin + cytarabine
Description: '7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azacitidine
Description: Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glasdegib
Description: Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
Study NCT03416179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cytarabine
Description: Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
Study NCT03416179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HSCT
Description: If required, and done per standard of care post Induction(s).
Study NCT03416179 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HSCT
Description: If required, and done per standard of care post Induction(s).
Study NCT02190201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope
Description: a kind of videolaryngoscopes, which are widely used in difficult airways.
Study NCT02190201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: A kind of traditional laryngoscopes
Study NCT02295319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual discharge
Description: See previous description in Arms
Study NCT01375101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patient is directed to use placebo capsule two times a day, ,until the one mouth
Study NCT01375101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
Study NCT02265653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS tablet C
Study NCT02265653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS tablet D
Study NCT02265653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS WIF tablet
Study NCT00324155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression
Study NCT00324155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT00324155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT00324155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT00825006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triple site pacing mode
Description: The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months.
Study NCT01532089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01532089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Given PO
Study NCT01532089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study NCT01532089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01532089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01532089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01532089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01031290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: daily sessions for 5 days
Study NCT01031290 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: daily sessions for 5 days
Study NCT01976182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
Study NCT01976182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
Study NCT06108921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol Powder
Description: The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of xylitol solution once a day for 2 months.
Study NCT06108921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salt Powder
Description: The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
Study NCT02852759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Cold
Description: The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.
Study NCT02852759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
Study NCT01568541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular toothpastes
Description: One tooth brushing
Study NCT01568541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Children's toothpastes
Description: One tooth brushing
Study NCT04010305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing BXCL501 (Dexmedetomidine)
Description: Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
Study NCT04010305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo film
Description: Placebo film for BXCL501
Study NCT04302597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Skin closure using surgical stapler.
Study NCT04302597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Description: Skin closure using 2-octylcyanoacrylate tissue adhesive.
Study NCT02153281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phenelzine treatment
Description: Subjects will have a PET and MRI scan before and after treatment with phenelzine.
Study NCT04277585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Early Psychosis Coordinated Specialty Care Services via telehealth.
Study NCT02806167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical algorithm
Description: Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
Study NCT03788330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fresh air system with filtration
Description: Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
Study NCT03788330 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fresh air system with filtration
Description: Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
Study NCT01186406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliadel
Description: Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
Study NCT01186406 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
Study NCT01186406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days.